Skip to content

Sarah Wang

NPI 1083298004ActiveIndividual· Obstetrics & Gynecology, Reproductive Endocrinology· New York, NY

Obstetrics & Gynecology, Reproductive Endocrinology in New York, New York, licensed in NY, with an NPI issued in May 2021. Part D covered 48 prescriptions written in 2024, 73% of them generic. Ferring Pharmaceuticals Inc. reported $147.40 in payments in 2025, mostly food and beverage.

Overview

NPI1083298004
StatusActive
Entity typeIndividual
Sole proprietorNo
NPI issuedMay 6, 2021
Last updated in NPPESJun 8, 2025
Certified by providerJun 8, 2025

Specialties and licenses

About license numbers in NPPES

Exclusion screening

ListResultDetails
HHS-OIG LEIE · Nov 10, 2026No matchChecked by NPI and by name + state
North Carolina Medicaid · Nov 11, 2026No match—
New York OMIG · Nov 11, 2026No match—
Ohio Medicaid · Nov 11, 2026No match—
Pennsylvania Medicheck · Nov 11, 2026No match—
Washington HCA · Nov 11, 2026No match—

Official OIG search · How matching works ·Bulk check a roster

Medicare

Enrollment (PECOS)Not in the public enrollment file of Oct 1, 2026

Part D prescriptions in 2024

Prescriptions (claims)48 · 53 30-day fills
Patients21
Total drug cost$3,039
Generic share73% of claims

Medicare sources and data years

Industry payments (Open Payments)

  • 2025$147.40 · 1 payment from 1 company

Top paying companies in 2025

CompanyAmountPayments
Ferring Pharmaceuticals Inc.$147.401

What the 2025 payments were for

  • Food and Beverage$147.40 · 1 payment

Receiving payments does not imply wrongdoing. What Open Payments covers ·original records

Other Obstetrics & Gynecology, Reproductive Endocrinology providers in New York

All 153 Obstetrics & Gynecology, Reproductive Endocrinology providers in New York · All Obstetrics & Gynecology, Reproductive Endocrinology providers in New York